Department of Clinical Cell Biology and FACS Core Unit, Children's Cancer Research Institute (CCRI), Vienna, Austria.
PLoS One. 2013 Apr 22;8(4):e59592. doi: 10.1371/journal.pone.0059592. Print 2013.
Adenoviral infections are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients. Adoptive transfer of donor-derived human adenovirus (HAdV)-specific T-cells represents a promising treatment option. However, the difficulty in identifying and selecting rare HAdV-specific T-cells, and the short time span between patients at high risk for invasive infection and viremia are major limitations. We therefore developed an IL-15-driven 6 to 12 day short-term protocol for in vitro detection of HAdV-specific T cells, as revealed by known MHC class I multimers and a newly identified adenoviral CD8 T-cell epitope derived from the E1A protein for the frequent HLA-type A*02∶01 and IFN-γ. Using this novel and improved diagnostic approach we observed a correlation between adenoviral load and reconstitution of CD8(+) and CD4(+) HAdV-specific T-cells including central memory cells in HSCT-patients. Adaption of the 12-day protocol to good manufacturing practice conditions resulted in a 2.6-log (mean) expansion of HAdV-specific T-cells displaying high cytolytic activity (4-fold) compared to controls and low or absent alloreactivity. Similar protocols successfully identified and rapidly expanded CMV-, EBV-, and BKV-specific T-cells. Our approach provides a powerful clinical-grade convertible tool for rapid and cost-effective detection and enrichment of multiple virus-specific T-cells that may facilitate broad clinical application.
腺病毒感染是儿科异基因造血干细胞移植(HSCT)后发病率和死亡率的主要原因。供体来源的人腺病毒(HAdV)特异性 T 细胞的过继转移是一种很有前途的治疗选择。然而,识别和选择罕见的 HAdV 特异性 T 细胞的困难,以及高侵袭性感染和病毒血症风险患者之间的时间间隔短,是主要的限制因素。因此,我们开发了一种基于 IL-15 的 6 至 12 天短期方案,用于体外检测 HAdV 特异性 T 细胞,方法是使用已知的 MHC Ⅰ类多聚体和新鉴定的源自 E1A 蛋白的腺病毒 CD8 T 细胞表位,该表位与常见的 HLA 型 A*02∶01 和 IFN-γ 相关。使用这种新的和改进的诊断方法,我们观察到腺病毒载量与 CD8(+)和 CD4(+)HAdV 特异性 T 细胞(包括中央记忆细胞)在 HSCT 患者中的重建之间存在相关性。将 12 天方案适应于良好生产规范条件,导致 HAdV 特异性 T 细胞的 2.6 对数(平均值)扩增,与对照相比,细胞毒性活性高(4 倍),而同种异体反应性低或不存在。类似的方案成功地鉴定和快速扩增了 CMV、EBV 和 BKV 特异性 T 细胞。我们的方法提供了一种强大的临床级可转换工具,用于快速、经济高效地检测和富集多种病毒特异性 T 细胞,这可能有助于广泛的临床应用。